385 related articles for article (PubMed ID: 25109853)
1. 3D tissue-engineered model of Ewing's sarcoma.
Lamhamedi-Cherradi SE; Santoro M; Ramammoorthy V; Menegaz BA; Bartholomeusz G; Iles LR; Amin HM; Livingston JA; Mikos AG; Ludwig JA
Adv Drug Deliv Rev; 2014 Dec; 79-80():155-71. PubMed ID: 25109853
[TBL] [Abstract][Full Text] [Related]
2. 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization.
Molina ER; Chim LK; Salazar MC; Koons GL; Menegaz BA; Ruiz-Velasco A; Lamhamedi-Cherradi SE; Vetter AM; Satish T; Cuglievan B; Smoak MM; Scott DW; Ludwig JA; Mikos AG
ACS Biomater Sci Eng; 2020 Jan; 6(1):539-552. PubMed ID: 33463239
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
4. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.
Santoro M; Menegaz BA; Lamhamedi-Cherradi SE; Molina ER; Wu D; Priebe W; Ludwig JA; Mikos AG
Tissue Eng Part A; 2017 Jan; 23(1-2):80-89. PubMed ID: 27923328
[TBL] [Abstract][Full Text] [Related]
5. Tissue-Engineered Model of Human Osteolytic Bone Tumor.
Villasante A; Marturano-Kruik A; Robinson ST; Liu Z; Guo XE; Vunjak-Novakovic G
Tissue Eng Part C Methods; 2017 Feb; 23(2):98-107. PubMed ID: 28068876
[TBL] [Abstract][Full Text] [Related]
6. Experimental therapies in Ewing's sarcoma.
Windsor R; Strauss S; Seddon B; Whelan J
Expert Opin Investig Drugs; 2009 Feb; 18(2):143-59. PubMed ID: 19236262
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
[TBL] [Abstract][Full Text] [Related]
10. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
11. Bioengineered Models of Solid Human Tumors for Cancer Research.
Marturano-Kruik A; Villasante A; Vunjak-Novakovic G
Methods Mol Biol; 2016; 1502():203-11. PubMed ID: 27115504
[TBL] [Abstract][Full Text] [Related]
12. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors.
Grier HE
Pediatr Clin North Am; 1997 Aug; 44(4):991-1004. PubMed ID: 9286296
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
14. Biomechanical regulation of drug sensitivity in an engineered model of human tumor.
Marturano-Kruik A; Villasante A; Yaeger K; Ambati SR; Chramiec A; Raimondi MT; Vunjak-Novakovic G
Biomaterials; 2018 Jan; 150():150-161. PubMed ID: 29040875
[TBL] [Abstract][Full Text] [Related]
15. Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study.
Kissane JM; Askin FB; Foulkes M; Stratton LB; Shirley SF
Hum Pathol; 1983 Sep; 14(9):773-9. PubMed ID: 6885037
[TBL] [Abstract][Full Text] [Related]
16. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.
Lissat A; Vraetz T; Tsokos M; Klein R; Braun M; Koutelia N; Fisch P; Romero ME; Long L; Noellke P; Mackall CL; Niemeyer CM; Kontny U
Am J Pathol; 2007 Jun; 170(6):1917-30. PubMed ID: 17525260
[TBL] [Abstract][Full Text] [Related]
18. An Innovative Therapeutic Option for the Treatment of Skeletal Sarcomas: Elimination of Osteo- and Ewing's Sarcoma Cells Using Physical Gas Plasma.
Jacoby JM; Strakeljahn S; Nitsch A; Bekeschus S; Hinz P; Mustea A; Ekkernkamp A; Tzvetkov MV; Haralambiev L; Stope MB
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585948
[TBL] [Abstract][Full Text] [Related]
19. Ewing's sarcoma: standard and experimental treatment options.
Subbiah V; Anderson P; Lazar AJ; Burdett E; Raymond K; Ludwig JA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):126-40. PubMed ID: 19533369
[TBL] [Abstract][Full Text] [Related]
20. Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.
Sampson VB; Kamara DF; Kolb EA
Expert Opin Drug Discov; 2013 Oct; 8(10):1181-9. PubMed ID: 23844615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]